13 December 2018 - - US-based contract research organisation Smithers Avanz's Bioanalytical Services division will expand its North American operations with the addition of a laboratory in New Jersey, the company said.

The new site will add 18,500 sq. ft of laboratory space to support client demand for services and will be GLP-, GCP-, GMP-compliant and CLIA certified.

As part of the expansion, the company will add translational science capabilities in drug discovery bioassays, biomarker discovery, mechanism of action studies, ultra-sensitive biomarker studies by HRMS, and others to support biotherapeutic development.

At the New Jersey site, Smithers Avanza will provide comprehensive bioanalytical services for gene therapy, CAR-T/TCR, vaccines, bi-/multi-specific antibodies, antibody-drug conjugates and biosimilar/bio betters among many other types of biologics. Smithers Avanza is currently hiring additional personnel to support the growth of these services and therapeutic areas.

The expansion is scheduled for completion in early 2019.

Smithers Avanza is a contract research organization supporting the pharmaceutical industry.

Its scientists have expertise in large molecule bioanalysis, assay development, validation and sample analysis at our GLP- and GCP-compliant and CLIA certified laboratory. 

Smithers Avanza Bioanalytical Services Division supports the development of biologics and vaccines from discovery through phase IV, with expertise that includes bioassays and high sensitivity assays. 

Smithers Avanza also offers preclinical toxicology and vaccine testing at our AAALAC-accredited facilities.